27 November 2016
Professor Dominique Belpomme: “Electrosensitivity is Not a Psychiatric Illness”
We have had another request for translation of an interview on electrohypersensitivity with Professor Dominique Belpomme.
Link to full text of study, “Reliable disease biomarkers characterizing and identifying electrohypersensitivity and multiple chemical sensitivity as two etiopathogenic aspects of a unique pathological disorder.”
Prof. Belpomme: “Electrosensitivity is not a psychiatric illness”
by Sylvie Dellus, santemagazine.fr, 11 January 2016 (translated by the Editor of “Towards Better Health”)
A battery of tests is sufficient to diagnose hypersensitivity to electromagnetic waves. The results of a study led by Prof. Belpomme have just been published in a scientific revue. He answers our questions.
For several years, Prof. Dominique Belpomme, oncologist, has been interested in the phenomenon of intolerance to electromagnetic waves (from cell phones, Wi-Fi…) and sensitivity to multiple chemical products, two syndromes which have many points in common.
Santé Magazine: Can we now diagnose electrosensitivity objectively?
Prof. Belpomme: Yes, it is what we are currently doing with sick people who come to see us. I do not sign a medical certificate without knowing the results of the battery of tests we have established. A clinical examination is not enough. We take into blood and urine tests and an echo-Doppler examination [échodoppler cérébral pulsé] which shows anomalies in the blood flow in the brain.
These tests are routinely proposed in Canada and in certain parts of the United States. In France, they are not possible in all laboratories and especially, for the echo-Doppler examination, we have only one machine available and it is located in Paris.
SM: Will the results that you published allow us to better understand the mechanism of the illness?
DB: Yes, it concerns inflammation which is located in the brain, a neuro-inflammation caused by electromagnetic fields. It is not a psychiatric or psychosomatic illness.
This neuro-inflammation liberates different elements, namely an increase in histamine in 40% of cases. There is also an oxidative stress mechanism identified thanks to a biological marker – increased nitrotyrosine in 28% of cases. But the phenomenon is without doubt much more complex with other possible markers.
SM: What is the hope of treatment for patients?
DB: Thanks to identification of these markers, we were able to establish treatment based on anti-histamines of the type H1 in persons where histomine has been increased and antioxidants where nitrotyrosine is too elevated. For revascularization of the brain, we resort to ginkgo biloba and fermented papaya.